Consistently, in an updated meta-analysis of 76 randomized trials involving 103,371 patients, results showed that GLP-1 RAs treatment was associated with increased risks of cholelithiasis, cholecystitis, and biliary disease (including bile duct obstruction, stenosis, and stone; biliary colic, cyst, and fistula; biliary tract cancer; cholecystectomy, cholecystitis, and cholelithiasis; and cholangitis), and showed a dose-response relationship [16]. The gene discussed is GLP1R; the disease is cholangitis.